Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep;205(3):833-839.
doi: 10.1111/bjh.19623. Epub 2024 Jul 1.

Diagnosis and initial treatment of transplant-eligible high-risk myeloma patients: A British Society for Haematology/UK Myeloma Society Good Practice Paper

Martin Kaiser  1   2 , Guy Pratt  3 , Ceri Bygrave  4 , Kristian Bowles  5 , Simon Stern  6 , Matthew Jenner  7 ; BSH Committee
Affiliations
Review

Diagnosis and initial treatment of transplant-eligible high-risk myeloma patients: A British Society for Haematology/UK Myeloma Society Good Practice Paper

Martin Kaiser et al. Br J Haematol. 2024 Sep.

Abstract

This Good Practice Paper provides recommendations for the diagnosis and initial management of transplant-eligible high-risk myeloma patients. It describes recent updates to the genetic diagnostics of high-risk myeloma and provides recommendations for treatment on the basis of recent prospective clinical trial evidence.

Keywords: high‐risk multiple myeloma; stratified treatment.

PubMed Disclaimer

References

REFERENCES

    1. van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397:410–427.
    1. Kumar SK, Rajkumar SV. The multiple myelomas – current concepts in cytogenetic classification and therapy. Nat Rev Clin Oncol. 2018;15:409–421.
    1. Gay F, Bertuglia G, Mina R. A rational approach to functional high‐risk myeloma. Hematology Am Soc Hematol Educ Program. 2023;2023:433–442.
    1. Bygrave C, Pawlyn C, Davies F, Craig Z, Cairns D, Hockaday A, et al. Early relapse after high‐dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high‐risk disease in multiple myeloma. Br J Haematol. 2021;193:551–555.
    1. Davies FE, Pawlyn C, Usmani SZ, San‐Miguel JF, Einsele H, Boyle EM, et al. Perspectives on the risk‐stratified treatment of multiple myeloma. Blood Cancer Discov. 2022;3:273–284.

LinkOut - more resources